CN103735616A - Microencapsulated preparation for protecting eyesight and preparation method thereof - Google Patents
Microencapsulated preparation for protecting eyesight and preparation method thereof Download PDFInfo
- Publication number
- CN103735616A CN103735616A CN201410028327.XA CN201410028327A CN103735616A CN 103735616 A CN103735616 A CN 103735616A CN 201410028327 A CN201410028327 A CN 201410028327A CN 103735616 A CN103735616 A CN 103735616A
- Authority
- CN
- China
- Prior art keywords
- preparation
- alpha
- phylloxanthin
- linolenic acid
- oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to a microencapsulated preparation for protecting eyesight and a preparation method thereof. The preparation essentially comprises a microencapsulated effective component consisting of lutein and alpha-linolenic acid. The preparation method comprises the following steps: respectively preparing an oil phase solution and an aqueous phase solution; mixing and emulsifying the solutions to prepare emulsion, or further drying to prepare particles. Match of lutein and alpha-linolenic acid is an important contribution of the invention, both lutein and alpha-linolenic acid can be used for protecting eyesight, and alpha-linolenic acid can be used for transferring lutein to macula lutea, so that the effect of relieving asthenopia and protecting eyesight of the product can be greatly improved. The preparation can be used for preparing solid electuary, liquid preparation, tablet candy or preparations in other modes for relieving asthenopia and protecting eyesight according to requirements.
Description
Technical field
The present invention relates to a kind of microencapsulation preparation for the protection of vision and preparation method thereof.
Background technology
Eye health is a lasting and important topic, and people never stop the concern of eye health.The quickening of the deterioration of sharply rising, the environment of Aged in China population quantity, life stress increase, epoch rhythm, has more aggravated generation and the development of oculopathy at present.There are in the market various eye protection products, enterprise's more natural extract of numerous and confused release or synthetic material or trace element are helped consumer's prevention or treat various eyes discomforts or ophthalmic, as cataract, senile degeneration of macula, myopia, asthenopia etc.In fact, the defect due to technology and scientific formulation having in these products, effect is not fully up to expectations.
In all eye protection compositions, phylloxanthin and Omega-3 are the natural essential nutrients that is present in eyes, and vision protection, alleviating asthenopia are had to very important effect.
Phylloxanthin is the Carotenoids being extensively present in the plants such as Fructus Cucurbitae moschatae, Radix Glycyrrhizae, Herba Spinaciae, marigold flower, the abundantest with the content in marigold flower.On mankind's eyes retina, contain abundant phylloxanthin, they are optionally deposited on macular area and whole retina, with density around the central fovea of macula lutea, for the highest, retinal periphery part reduces gradually, and macular pigment can effectively absorb royal purple light and prevent the amphiblestroid damage of radical pair.Phylloxanthin in plant has two kinds of existence forms, phylloxanthin monomer and lutein ester, and phylloxanthin monomer can directly absorbed by the bodyly utilize, and lutein ester is absorbed by body by being hydrolyzed in vivo free lutein.Research shows; after being absorbed by the body, phylloxanthin and lutein ester can bring into play the effect of kinds of protect vision; as prevent age related macular degeneration, senile cataract (B Olmedilla; et al.J Sci Food Agr81(9): 904-909; 2001) and effectively improve asthenopia (Liu Ji etc.; Chinese Pharmaceutical Affairs, 26(8): 902-905,2012).In actual production, phylloxanthin and the less stable of lutein ester crystal to light, heat, air, hydrophobicity has limited again the scope of its application, and fat this affect them and can cause this type of preparation to have the defects such as bioavailability difference is large, individual variation is large in the key factor of intestinal absorption.Find new phylloxanthin/lutein ester preparation technique and formula, improving bioavailability, reduce individual variation impact, to expand its range of application in aqueous systems food be the important topic facing in current exploitation.
Alpha-linolenic acid is a kind of polyunsaturated fatty acid, belongs to Omega-3 unsaturated fatty acid series, has fusing point low, water insoluble, is soluble in the characteristic of non-polar solven.Be placed in air easily oxidized.Alpha-linolenic acid is essential fatty acid, can metabolism generate EPA and the DHA that belongs to Omega-3 series in vivo, in the main phospholipid of retinal light injury photoreceptor film, DHA accounts for 40～60%(Neuringer M.Am J Clin Nutri.71:256-267 of total fatty acids, 2000).Alpha-linolenic acid to optic nerve, cardiovascular and cerebrovascular disease, anticancer etc. have certain beneficial effect (Andrew J.S, et al.Lipids.37(12): 1113-1123,2002).Research also shows, the absorption of Omega-3 unsaturated fatty acid can improve human body to the bioavailability (Huang Yang wood of phylloxanthin etc., Chinese Non communicable disease, 18(5): 546-549,2010).
Based on noted earlier, there are in the market numerous eye protection products, but they are mostly the soft capsule dosage forms that contains phylloxanthin or contain alpha-linolenic acid, as CN102726734A mentions with comprising main component phylloxanthin and Semen Lini oil, make soft capsule alleviating asthenopia and improve vision; For CN1634015A, phylloxanthin, β-carotenoid, gamma-Linolenic acid and alpha-linolenic acid are made prevention ophthalmic vision protection, the prophylaxis of cancer etc. such as soft capsule, drop pill; The phylloxanthin that CN1771919A extracts with supercritical extraction process and alpha-linolenic acid are made soft capsule prevention and are treated senile macular degeneration disease, cataract and cardiovascular and cerebrovascular disease.These formula for a product are all more single, and bioavailability is low, and the finished dosage forms of making is soft capsule, and for the crowd of child, old man and other dysphagia, limitation is more obvious.
Exploitation nanoscale cold water dispersion type xanthophyll and alpha-linolenic acid microcapsule powder not only can increase the stability of active substance; expand its range of application in aqueous phase system; and nano level particle diameter can better be absorbed by the body; add the synergistic function between phylloxanthin and alpha-linolenic acid, guarantee that product efficiently brings into play the effects such as vision protection, alleviating asthenopia, prevention ophthalmic comprehensively.
Summary of the invention
The invention provides that a kind of bioavailability is high, good stability, the microencapsulation preparation for the protection of vision that is more easily absorbed by the body.
Technical scheme of the present invention is:
For the protection of a microencapsulation preparation for vision, this microencapsulation preparation is that the component by following weight portion is prepared from: functional component 20.6-36 part, oil phase antioxidant 1-3 part, wall material 20-42 part, water antioxidant 0.5-2 part, filler 18-40 part;
Wherein said functional component comprises phylloxanthin or lutein ester crystal 0.6-1 part, contains vegetable oil 20-35 part of 40～60% alpha-linolenic acids; Described phylloxanthin or lutein ester crystal extract and obtain in Flos Tagetis Erectae, and purity is 60～90%.
Vegetable oil containing alpha-linolenic acid of the present invention is one or more mixture that form with arbitrary proportion in Semen Lini oil, perilla oil, walnut oil or seed of black currant oil; Especially preferred perilla oil or Semen Lini oil.
Oil phase antioxidant of the present invention be propyl gallate, dibenzylatiooluene, Butylated hydroxyanisole, tert-butyl hydroquinone, Herba Rosmarini Officinalis, one or more mixture that form with arbitrary proportion in dl-alpha-tocopherol, mixed tocopherol and phospholipid; Especially preferably the mixture that mixed tocopherol and phospholipid form with arbitrary proportion.
The present invention is not particularly limited described wall material, and this area normally used wall material raw material can be used.Preferred wall material is one or both mixture that form with arbitrary proportion in modification arabic gum, modified starch, casein, pectin, sodium carboxymethylcellulose pyce, Carboxymethyl cellulose sodium, sodium alginate; Especially preferred is modification arabic gum or modified starch; Most preferably arabic gum, through OSA(ocentyl succinic) modification arabic gum or OSA modified starch.
Water antioxidant of the present invention is one or both mixture that form with arbitrary proportion in sodium ascorbate, ascorbyl palmitate and tea polyphenols; Especially preferably the mixture forming with arbitrary proportion with sodium ascorbate and ascorbyl palmitate.
To the phylloxanthin using as raw material in the present invention or lutein ester crystal purity, there is no particular limitation, and by calculating, those of ordinary skill in the art easily determines that take the phylloxanthin of different purity or lutein ester produces required consumption as initiation material.In the preferred embodiment of the present invention, phylloxanthin or lutein ester crystal purity are 60%～90%, preferably in Flos Tagetis Erectae, extract and obtain, and extracting method is the conventional method in this area, and it will not go into details in the present invention.
To described filler, there is no particular limitation in the present invention, and the normally used filler in this area can be used in the present invention, and as white sugar, glucose, lactose, maltose or oligomeric isomaltose etc., the present invention preferably uses maltodextrin.
The preparation method of the described microencapsulation preparation for the protection of vision of the present invention, comprises the steps:
(1), under 40～80 ℃ of conditions, by mass parts, phylloxanthin or lutein ester crystal and oil phase antioxidant are joined containing stirring and dissolving in the vegetable oil of 40～60% alpha-linolenic acids and obtain solution I;
(2) under 50～80 ℃ of conditions, wall material, filler and water antioxidant are added to the water, stirring and dissolving obtains solution II;
Wherein the consumption of water is 1～8 times of non-water raw material gross mass;
(3) solution I and solution II mixing and emulsifying are 0.5～5 hour, and gained emulsion obtains homogeneous emulsion through 10～100Mpa high pressure homogenize;
(4) spraying of the homogeneous emulsion of step (3) is dried to obtain phylloxanthin-alpha-linolenic acid microcapsule powder.
In above-mentioned preparation method, the phylloxanthin-alpha-linolenic acid microcapsule powder obtaining in step (4), can further be prepared into solid granules, liquid agent, pressed candy or other form preparation as required.
Microencapsulation preparation for the protection of vision of the present invention, the vegetable oil that will arrange in pairs or groups phylloxanthin (or lutein ester) and contain alpha-linolenic acid, as functional component, is equipped with microcapsule wall material, filler and antioxidant and prepares microencapsulation preparation.And the vegetable oil that contains alpha-linolenic acid, it is functional component, can directly dissolve fat-soluble functional component again, and can play the effect of emulsifying agent, make not contain in preparation the conventional adjuvant in microencapsulation preparation at present such as any organic solvent or emulsifying agent, greatly increase the safety of product, reduced the cost of product.In the present invention, alpha-linolenic acid has been brought into play the triple role of functional component, oil-phase component and emulsifying agent simultaneously.
Microencapsulation preparation of the present invention, the effect with good vision protection, experimental result shows that functional component is after microencapsulation is processed, stability to pH, light, heat and oxygen is all significantly increased, be conducive to strengthen human body to phylloxanthin/ester and Omega-3(alpha-linolenic acid a kind of for wherein) bioavailability; Experimental result also shows that unsaturated fatty acid Omega-3 can significantly improve the concentration of HDL-C in blood circulation, as from blood, phylloxanthin being transported to the carrier instrument of eyes, the increase of its concentration, has guaranteed that phylloxanthin arrives the biopotency of macula lutea performance eye protection effect greatly.
Microencapsulation preparation of the present invention, is dispersed in non-water-soluble phylloxanthin and alpha-linolenic acid in cold water with the form of sub-nanoparticle completely, and nutritional labeling is through microencapsulated encapsulate rear stability is good, color even is lasting, bioavailability is high.
Microencapsulation preparation of the present invention, its preparation method environmental protection is simple, does not introduce organic solvent, and industrialization is simple, can be widely used in solid granules, liquid agent, pressed candy or other form preparation.
Each technical characterictic of the present invention supports one another in function, and has obtained new technique effect.Aspect function supports one another, alpha-linolenic acid is playing the triple role of functional component, oil-phase component and emulsifying agent, can improve the bioavailability of phylloxanthin (or lutein ester) simultaneously.And the present invention, by phylloxanthin (or lutein ester) and the vegetable oil microencapsulation that contains alpha-linolenic acid, has also supported the bioavailability of these two kinds of functional components.Aspect new technique effect, the present invention has improved the bioavailability of functional component, has avoided with an organic solvent, having increased Product Safety, and can reduce product cost by reducing functional component, oil-phase component and emulsifier.
The technique effect that the present invention is used in combination after phylloxanthin (or lutein ester) and alpha-linolenic acid is more superior than using separately the summation of phylloxanthin (or lutein ester) and alpha-linolenic acid effect: use separately phylloxanthin (or lutein ester) or alpha-linolenic acid, need to reach larger amount just can play certain effect; And the present invention is used in combination after phylloxanthin (or lutein ester) and alpha-linolenic acid, alpha-linolenic acid, in as functional component, can improve the bioavailability of phylloxanthin (or lutein ester).Like this, these two kinds of functional components are supported mutually, have played the effect of Synergistic, more superior than the summation of every kind of functional component, make technical combinations of the present invention have outstanding substantive distinguishing features and significant progressive.
Accompanying drawing explanation
Fig. 1 is the Detection of Stability result of phylloxanthin under condition of different pH (A) and phylloxanthin-alpha-linolenic acid microcapsule powder of the present invention (B).
Fig. 2 is the light stability testing result (illumination condition: ultraviolet radiation, wavelength 254nm) of phylloxanthin (A) and phylloxanthin-alpha-linolenic acid microcapsule powder of the present invention (B).
Fig. 3 is the heat stability test result (temperature: 80 ± 2 ℃) of phylloxanthin (A) and phylloxanthin-alpha-linolenic acid microcapsule powder of the present invention (B).
Fig. 4 is phylloxanthin (A) and the Detection of Stability result of phylloxanthin-alpha-linolenic acid microcapsule powder of the present invention (B) in mobile oxygen.
Fig. 5 changes for supplementing total high density lipoprotein cholesterol level in the human body of alpha-linolenic acid supplementary front and back, * in Fig. 5, and P < 0.05, difference has significance.
The specific embodiment
For of the present invention may combination is clearly described, following examples are provided, but are never in order to limit the present invention, and scope of the present invention is not subject to the limitation of illustrated embodiment.
Formula:
Preparation technology: 1., under 50 ℃ of conditions, OSA modified starch, maltodextrin, sodium ascorbate and ascorbyl palmitate are added in 575ml water, stirring and dissolving obtains aqueous phase solution; 2. under 45 ℃ of conditions, mixed tocopherol, sunflower phospholipid, lutein crystal (purity 65%) are added in perilla oil, stirring and dissolving obtains oil-phase solution; 3. aqueous phase solution and oil-phase solution mixing and emulsifying 5h, gained emulsion is through 20Mpa high pressure homogenize, the dry cold water dispersion type compound xanthophyll-alpha-linolenic acid microcapsule powder that obtains of spraying, be prepared into packing specification 4g/ bag, dose is the compound xanthophyll solid granules of 1 bag of every day.
Formula:
Preparation technology: with embodiment 1, lutein ester crystal purity 80%, final compound xanthophyll ester solid granules, packing specification 1g/ bag, 1 bag of every day.
Formula:
Preparation technology: microencapsulation processing technology is with embodiment 1, lutein ester crystal purity 80%.The microcapsule making mixes with mannitol, vitamin C, calcium hydrogen phosphate, stearyl ester magnesium, Polyethylene Glycol, anhydrous citric acid and aspartame by granulating, tabletting makes finished product after dry, granulate, mixing, specification 1g/ sheet, and every day, dose was 4.
Formula:
Preparation technology: 1., under 50 ℃ of conditions, OSA modified starch, maltodextrin, sodium ascorbate and ascorbyl palmitate are added in 595ml water, stirring and dissolving obtains aqueous phase solution; 2. under 45 ℃ of conditions, mixed tocopherol, Herba Rosmarini Officinalis and lutein ester crystal (purity 60%) are added in perilla oil, stirring and dissolving obtains oil-phase solution; 3. aqueous phase solution and oil-phase solution mix, and mend and add water to 24000ml, emulsifying 5h, gained emulsion is sent into racking machine by every bottle of 10ml subpackage after 20Mpa high pressure homogenize, Zha Gai, packing, check, qualified finished product, 2 of every days.
1, microencapsulation structure improves the stability of phylloxanthin to pH, light, heat and oxygen
Make the method for embodiment 1 prepare compound xanthophyll-alpha-linolenic acid microcapsule powder and be made as test group (B), take lutein crystal as matched group (A), respectively B and A are carried out to the study on the stability (Fig. 1) under condition of different pH, to the study on the stability of light (Fig. 2), to heat stability investigation (Fig. 3) with to the study on the stability of oxygen (Fig. 4).Result by Fig. 1～4 can be seen; phylloxanthin is after microencapsulation is processed; capsule material plays a very good protection to phylloxanthin; its stability to pH, light, heat and oxygen is all significantly improved, the bioavailability after being conducive to improve it and arriving in human body and bring into play to greatest extent biopotency.
Aforementioned stable is investigated in test:
Study on the stability method under condition of different pH is: test group and matched group are placed in respectively to the solution of pH1～14, after 1 hour, are determined at respectively the content of the phylloxanthin in sample under condition of different pH.
Study on the stability method to light is: it is 254nm irradiation under ultraviolet ray environment that test group and matched group are placed in respectively to wavelength, and the content of working sample Lutein during respectively at 0,1,2,3,4,5,6 week.
To heat stability investigation method, be: it is the dark surrounds of 80 ± 2 ℃ that test group and matched group are placed in respectively to temperature, and respectively at the content of working sample Lutein after 0.0,0.5,1.0,1.5,2.0,2.5,3.0 hour.
Study on the stability method to oxygen is: test group and matched group are placed in respectively to the dark surrounds that has mobile oxygen to exist at 25 ℃, and the content of working sample Lutein during respectively at 0,1,2,3,4,5,6 week.
2,1,2,3,4 four samples of embodiment at room temperature keep in Dark Place, place 3,6,9,12,15,18,21,24 months, check on time, the outward appearance of each sample does not all change, effective ingredient (phylloxanthin/lutein ester and alpha-linolenic acid) does not change through check yet, peroxide value is constant, phylloxanthin-perilla oil solution of take is matched group simultaneously, and under the same terms and time, investigate its outward appearance, effective ingredient and peroxide value desired value, the indices of result reference substance in the time of 3rd month is defective.By the result of table 2, can think that various microencapsulation formulation products of the present invention and various prescription all can reach the shelf-life of 2 years.
Table 2. stability experiment result
The bioavailability test of embodiment 6 microcapsule formulations
1, the male that 10 ages are 25 ± 1.5 is chosen in experiment, 4 weeks alpha-linolenic acid supplementarys (commercially available) of continuous supplementation, before supplementing and after supplementing, measure respectively its blood plasma HDL-C concentration, the results are shown in accompanying drawing 5, as seen from Figure 5, alpha-linolenic acid replenisher can significantly increase HDL-C concentration in body, thereby transport more phylloxanthin, arrives eyes macula lutea position, increases the degree of absorbing of human body to phylloxanthin.
Phylloxanthin and alpha-linolenic acid are all respectively the natural functional components of protection eyes, just have synergistic function when the two is applied together.Known, the vehicle that phylloxanthin is transported to site of action in human body is HDL-C(HDL-C), in embodiment in product containing the vegetable oil of alpha-linolenic acid except as prevention ophthalmic, improve asthenopic composition, the amount that also can significantly improve HDL-C in human body, makes phylloxanthin arrive more efficiently eye.
2, the phylloxanthin raw material of microencapsulation does not adopt intestinal perfusion experiment with the Xanthin micro-capsule making by invention same procedure simultaneously, the concentration of determined by ultraviolet spectrophotometry intestinal perfusate Lutein, and the reduction according to it in little intestinal segment is determined its absorbtivity.Experimental result finds, Xanthin micro-capsule with without microencapsulation, compare, absorbance brings up to 58.34% by 33.29%, bioavailability significantly improves.
The effect experiment of embodiment 7 microcapsule formulations
The alleviating asthenopia method of inspection
1 experimenter's inclusive criteria
1.1 children and adolescents or adult
1.2 is long-term with eye, view fatiguability person
2 experimenter's exclusion standards
2.1 do not meet the experimenter who includes age criterion in: to experiment health food allergy sufferers.
2.2 suffer from infectious ocular disease person.
The diseases such as 2.3 suffer from fundus oculi disease or Quan Bingyou must blood vessel, cerebrovascular, liver, kidney, hemopoietic system.
2.4 take the article relevant with tested function in a short time, have influence on the judgement person to result.
2.5 long-term takings other about medicine or use other Therapeutic Method, fail terminator.
2.6 do not meet inclusive criteria, and not credit in accordance with regulations, or data is not congruent affects effect or safety judgement person.
3 EXPERIMENTAL DESIGN and grouping requirement
Adopt two kinds of control design between self and group.According to requirement random, double blinding, divide into groups, during grouping, according to symptom and view, check situation, make symptom and the view horizontal equalization of test group and matched group, will consider the factors such as age, sex simultaneously, make between group, to there is comparability.Blank group (soft capsule that edible soybean oil is made) 30 people, phylloxanthin folk prescription soft capsule (commercially available) matched group a30 people, Semen Lini oil soft capsule (commercially available) matched group b30 people, test group (tablet that edible embodiment 3 makes) 30 people.
The dosage of 4 tested materials and using method
Test group is taken tested amount by recommend method and recommended amounts, each 4 once a day; Blank group and matched group a, b each 1 once a day.Take 30 days time limits.
5 observation index and effect criterion
Ophthalmologic examination: ophthalmalgia, ophthalmic bloated, photophobia, blurred vision, the symptom such as dry and astringent.
Symptom is improved: ophthalmalgia, ophthalmic bloated, photophobia, blurred vision, the dry and astringent arbitrary symptom improvement of eye are " improvement " for 1 minute and 1 minute above, and 5 kinds of arbitrary improvement of symptom and other symptom judge symptom improvement without worsening.
Invalid: not reach above-mentioned standard.
Asthenopia symptom decision method: as table 3.
Table 3. asthenopia symptom decision method
Note: " random thoughts " refer to 1～2 time/2 days, " time have " refers to 1～3 times/day, " often " refers to 3 times/day of >
6 experimental results
Matched group a, b and test group are all improved, and blank group is without any improvement.The results are shown in following table 4.
Table 4. microencapsulation preparation of the present invention is to asthenopic effect
The microcapsule formulation of a kind of vision protection of tested material is compared with separately supplementary xanthophyll soft capsule or alpha-linolenic acid soft capsule; improvement number and improvement rate for experimenter's asthenopia symptom have greater advantage, can judge: simultaneously containing the remarkable alleviating asthenopia of the microcapsule formulation (microencapsulation preparation of the present invention) of phylloxanthin and alpha-linolenic acid.
Claims (5)
1. the microencapsulation preparation for the protection of vision, it is characterized in that, this microencapsulation preparation is that the component by following weight portion is prepared from: functional component 20.6-36 part, oil phase antioxidant 1-3 part, wall material 20-42 part, water antioxidant 0.5-2 part, filler 18-40 part;
Wherein said functional component contains phylloxanthin or lutein ester crystal 0.6-1 part and contains vegetable oil 20-35 part of 40～60% alpha-linolenic acids; Described phylloxanthin or lutein ester crystal extract and obtain in Flos Tagetis Erectae, and purity is 60～90%.
2. the microencapsulation preparation for the protection of vision according to claim 1; it is characterized in that, the described vegetable oil containing alpha-linolenic acid is one or more mixture that form with arbitrary proportion in Semen Lini oil, perilla oil, walnut oil or seed of black currant oil.
3. the microencapsulation preparation for the protection of vision according to claim 1, it is characterized in that, described oil phase antioxidant be propyl gallate, dibenzylatiooluene, Butylated hydroxyanisole, tert-butyl hydroquinone, Herba Rosmarini Officinalis, one or more mixture that form with arbitrary proportion in dl-alpha-tocopherol, mixed tocopherol and phospholipid; Described water antioxidant is one or both mixture that form with arbitrary proportion in sodium ascorbate, ascorbyl palmitate and tea polyphenols; Described wall material is at least one in modification arabic gum, modified starch and casein.
4. the preparation method of the microencapsulation preparation for the protection of vision claimed in claim 1, comprises the steps:
(1), under 40～80 ℃ of conditions, by mass parts, phylloxanthin or lutein ester crystal, oil phase antioxidant are joined containing stirring and dissolving in the vegetable oil of 40～60% alpha-linolenic acids and obtain solution I;
(2) under 50～80 ℃ of conditions, wall material, filler and water antioxidant are added to the water, stirring and dissolving obtains solution II;
Wherein the consumption of water is 1～8 times of non-water raw material gross mass;
(3) solution I and solution II mixing and emulsifying are 0.5～5 hour, and gained emulsion obtains homogeneous emulsion through 10～100Mpa high pressure homogenize;
(4) spraying of the homogeneous emulsion of step (3) is dried to obtain phylloxanthin-alpha-linolenic acid microcapsule powder.
5. preparation method according to claim 4, is characterized in that, described phylloxanthin-alpha-linolenic acid microcapsule powder is prepared into the acceptable preparation of solid granules, liquid agent or pressed candy.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410028327.XA CN103735616A (en) | 2014-01-20 | 2014-01-20 | Microencapsulated preparation for protecting eyesight and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410028327.XA CN103735616A (en) | 2014-01-20 | 2014-01-20 | Microencapsulated preparation for protecting eyesight and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103735616A true CN103735616A (en) | 2014-04-23 |
Family
ID=50492731
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410028327.XA Pending CN103735616A (en) | 2014-01-20 | 2014-01-20 | Microencapsulated preparation for protecting eyesight and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103735616A (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104544092A (en) * | 2015-01-29 | 2015-04-29 | 王维义 | Linseed oil microcapsule powder and preparation process thereof |
| CN105029409A (en) * | 2015-06-24 | 2015-11-11 | 芦冰 | Flaxseed oil microcapsule powder and preparation method thereof |
| CN105341929A (en) * | 2015-12-02 | 2016-02-24 | 烟台燕园科玛健康产业有限公司 | Health-care food composition capable of alleviating asthenopia |
| CN103947770B (en) * | 2014-05-16 | 2016-03-09 | 普洱联众生物资源开发有限公司 | A kind of crude vegetal being conducive to eyesight |
| WO2016119143A1 (en) * | 2015-01-28 | 2016-08-04 | 晨光生物科技集团股份有限公司 | Lutein microcapsule preparation and preparation method |
| CN106072584A (en) * | 2016-07-13 | 2016-11-09 | 大兴安岭超越野生浆果开发有限责任公司 | A kind of lutein ester and the compound edible health care product of Oleum Hippophae |
| CN106260417A (en) * | 2016-08-09 | 2017-01-04 | 北京斯利安药业有限公司 | A kind of compositions containing phylloxanthin and the pressed candy of preparation thereof |
| CN109123674A (en) * | 2018-09-05 | 2019-01-04 | 江苏道诚生物科技有限公司 | A kind of black fruit fructus lycii compound alleviation visual fatigue piece and its preparation process |
| CN109567169A (en) * | 2018-12-29 | 2019-04-05 | 北京金康普食品科技有限公司 | Microencapsulation nanometer formulation of micronutrient premix and preparation method thereof |
| CN110179038A (en) * | 2019-07-04 | 2019-08-30 | 江苏汉典生物科技股份有限公司 | A kind of formula and processing technology of lutein ester effervescent tablet |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1771919A (en) * | 2005-10-28 | 2006-05-17 | 江苏瑞迪生科技有限公司 | Compound soft lutein capsule and its prepn process |
| CN1917946A (en) * | 2003-12-18 | 2007-02-21 | Gat制剂有限公司 | Continuous multi-microencapsulation process for improving the stability and storage life of biologically active ingredients |
| CN101292965A (en) * | 2007-04-24 | 2008-10-29 | 沈阳皓天万嘉医药科技有限公司 | Beta-carotene microcapsule and preparation method thereof |
| CN101548962A (en) * | 2009-05-12 | 2009-10-07 | 南京泽朗医药科技有限公司 | Preparation method of lutein microcapsule |
| CN102389108A (en) * | 2011-10-10 | 2012-03-28 | 大连医诺生物有限公司 | Lutein ester microcapsule powder and preparation method thereof |
| CN103202351A (en) * | 2013-04-23 | 2013-07-17 | 山东省恒兴油脂有限公司 | Functional grease composition and preparation method thereof |
-
2014
- 2014-01-20 CN CN201410028327.XA patent/CN103735616A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1917946A (en) * | 2003-12-18 | 2007-02-21 | Gat制剂有限公司 | Continuous multi-microencapsulation process for improving the stability and storage life of biologically active ingredients |
| CN1771919A (en) * | 2005-10-28 | 2006-05-17 | 江苏瑞迪生科技有限公司 | Compound soft lutein capsule and its prepn process |
| CN101292965A (en) * | 2007-04-24 | 2008-10-29 | 沈阳皓天万嘉医药科技有限公司 | Beta-carotene microcapsule and preparation method thereof |
| CN101548962A (en) * | 2009-05-12 | 2009-10-07 | 南京泽朗医药科技有限公司 | Preparation method of lutein microcapsule |
| CN102389108A (en) * | 2011-10-10 | 2012-03-28 | 大连医诺生物有限公司 | Lutein ester microcapsule powder and preparation method thereof |
| CN103202351A (en) * | 2013-04-23 | 2013-07-17 | 山东省恒兴油脂有限公司 | Functional grease composition and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 孙平主编: "《食品添加剂》", 30 September 2009, 中国轻工业出版社 * |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103947770B (en) * | 2014-05-16 | 2016-03-09 | 普洱联众生物资源开发有限公司 | A kind of crude vegetal being conducive to eyesight |
| WO2016119143A1 (en) * | 2015-01-28 | 2016-08-04 | 晨光生物科技集团股份有限公司 | Lutein microcapsule preparation and preparation method |
| US11278856B2 (en) | 2015-01-28 | 2022-03-22 | Chenguang Biotech Group Co., Ltd | Lutein microcapsule formulation and preparation method thereof |
| CN104544092A (en) * | 2015-01-29 | 2015-04-29 | 王维义 | Linseed oil microcapsule powder and preparation process thereof |
| CN105029409A (en) * | 2015-06-24 | 2015-11-11 | 芦冰 | Flaxseed oil microcapsule powder and preparation method thereof |
| CN105341929A (en) * | 2015-12-02 | 2016-02-24 | 烟台燕园科玛健康产业有限公司 | Health-care food composition capable of alleviating asthenopia |
| CN106072584A (en) * | 2016-07-13 | 2016-11-09 | 大兴安岭超越野生浆果开发有限责任公司 | A kind of lutein ester and the compound edible health care product of Oleum Hippophae |
| CN106260417A (en) * | 2016-08-09 | 2017-01-04 | 北京斯利安药业有限公司 | A kind of compositions containing phylloxanthin and the pressed candy of preparation thereof |
| CN109123674A (en) * | 2018-09-05 | 2019-01-04 | 江苏道诚生物科技有限公司 | A kind of black fruit fructus lycii compound alleviation visual fatigue piece and its preparation process |
| CN109567169A (en) * | 2018-12-29 | 2019-04-05 | 北京金康普食品科技有限公司 | Microencapsulation nanometer formulation of micronutrient premix and preparation method thereof |
| CN110179038A (en) * | 2019-07-04 | 2019-08-30 | 江苏汉典生物科技股份有限公司 | A kind of formula and processing technology of lutein ester effervescent tablet |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103735616A (en) | Microencapsulated preparation for protecting eyesight and preparation method thereof | |
| CN105613789B (en) | High-fat high-dietary-fiber composite animal and plant powdered oil and fat, and preparation method and application thereof | |
| CN108112762B (en) | Novel functional soft sweet and preparation method thereof | |
| EP2138055B1 (en) | Formula food to be beneficial for visuognosis persistence and use thereof | |
| CN102552549B (en) | Composition for improving visual fatigue and preparation method and application thereof | |
| CN104397311A (en) | Blueberry composite tablet candy capable of relieving visual fatigue and preparation method thereof | |
| US20210177013A1 (en) | Water-soluble formulations, methods of making and use | |
| CN104839688A (en) | Eye care preparation and preparation method thereof | |
| RU2771527C1 (en) | Solubilisate with curcumin and at least one cannabinoid as an additional active substance | |
| CN108041609B (en) | Food composition with functions of relieving visual fatigue and preventing myopia and preparation method thereof | |
| CN104474018A (en) | Health-care soft capsule for relieving asthenopia | |
| CN107307390A (en) | Function nutrition hardening agent composition and preparation method | |
| CN104323283A (en) | Coenzyme Q10-containing nutritional composition as well as preparation method and application of coenzyme Q10-containing nutritional composition | |
| US20110189319A1 (en) | Lifeforce liquid supplement | |
| CN105394749A (en) | Formula, preparation method and application of astaxanthin-containing health food | |
| CN105595341B (en) | A kind of lycopene composition with anti-oxidant alleviation visual fatigue | |
| CN100486456C (en) | Health-care food used for reliefing eyestrain, and its preparing method | |
| CN107296278A (en) | A kind of function nutrition hardening agent composition and preparation method thereof | |
| CN111567805A (en) | Water-soluble haematococcus pluvialis astaxanthin soft capsule and preparation method thereof | |
| CN106491667B (en) | Pomegranate extract with high ellagic acid content for relieving menopausal symptoms in women | |
| JP6211220B1 (en) | Anthocyanin-containing composition for capsule and capsule | |
| CN100387154C (en) | Health-care food for relieving-vision fatigue and its prepn. method | |
| Siripongvutikorn et al. | Some factors affecting the bioactive substances of lactogenic tea | |
| JP5886457B1 (en) | Anthocyanin-containing composition for capsule and capsule | |
| CN108379446B (en) | Coenzyme Q10 preparation for adjuvant treatment of male oligospermia and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140423 |
|
| RJ01 | Rejection of invention patent application after publication |